You are here » Home » Companies » Company Overview » Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd.

BSE: 507789	Sector: Health care
NSE: JAGSNPHARM	ISIN Code: INE048B01027

BSE 12:51 | 07 Feb

327.35

-0.95
(-0.29%)

OPEN

330.95

HIGH

331.95

LOW

325.00

NSE 12:39 | 07 Feb

327.40

-0.15
(-0.05%)

OPEN

327.05

HIGH

331.85

LOW

324.05

Add to Watchlist | Add to Portfolio

OPEN	330.95
PREVIOUS CLOSE	328.30
VOLUME	682
52-Week high	420.20
52-Week low	156.75
P/E	41.59
Mkt Cap.(Rs cr)	858
Buy Price	327.00
Buy Qty	101.00
Sell Price	328.50
Sell Qty	2.00

OPEN	330.95
CLOSE	328.30
VOLUME	682
52-Week high	420.20
52-Week low	156.75
P/E	41.59
Mkt Cap.(Rs cr)	858
Buy Price	327.00
Buy Qty	101.00
Sell Price	328.50
Sell Qty	2.00

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) - News Sector

Stay selective on defensives amid current market volatility: Analysts

12.51 pm | 7 Feb 2023 | Business Standard

Given the uncertainty on how the market trajectory may play out ahead, analysts believe investors can rotate allocation from high beta stocks to defen...
Stay selective on defensives amid current market volatility: Analysts

12.51 pm | 7 Feb 2023 | Business Standard

Given the uncertainty on how the market trajectory may play out ahead, analysts believe investors can rotate allocation from high beta stocks to defen...
P&G Health soars 15% after PAT jumps 71% YoY in December quarter results

11.17 am | 6 Feb 2023 | Business Standard

The management said that the higher PAT growth was supported by improved margin through portfolio premiumisation, healthy mix and optimization of expe...
Divi's Labs stock tanks 12% on big miss in Q3; near-term trend 'bearish'

12.21 am | 4 Feb 2023 | Business Standard

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish
Divi's Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected

2.26 pm | 3 Feb 2023 | Business Standard

In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall ...
Business initiative that has a heart: Lupin eyes Lyfe beyond the pill

6.59 pm | 2 Feb 2023 | Business Standard

Its digital health initiative for cardiac patients is part of its strategy to diversify into healthcare services
Sun Pharma Q3 net profit up 5.2% as sales grow in India, US markets

10.36 pm | 31 Jan 2023 | Business Standard

Company says specialty products will continue as growth driver, will scale up investment for it
Laurus Labs slips 5%, hits over 2-year low post December quarter results

3.13 pm | 31 Jan 2023 | Business Standard

Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment
Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low

11.23 am | 31 Jan 2023 | Business Standard

Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per ce...
Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low

11.23 am | 31 Jan 2023 | Business Standard

Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per ce...
Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low

11.23 am | 31 Jan 2023 | Business Standard

Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per ce...
Alkem launches novel antibiotic combination for drug-resistant infections

6.24 pm | 30 Jan 2023 | Business Standard

The formulation, to be sold under the Zidavi brans for Rs 2,700 a vial, has been approved by US FDA, European Medicines Agency, and CDSCO
Sun Pharma nears 52-week high ahead of Q3 results; stock up 7% in a month

11.56 am | 30 Jan 2023 | Business Standard

In the past one month, Sun Pharma outperformed market as shares surged 7 per cent, as compared to 2.5 per cent decline in the S&P BSE Sensex
Enzene Biosciences raises $50 million, aims to expand into global markets

12.22 am | 30 Jan 2023 | Business Standard

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd
Flows to Indian equities are at risk as investors eye China: Chris Wood

10.55 pm | 27 Jan 2023 | Business Standard

He believes India remains the best long-term equity story in Asian and the emerging market (EM) context
Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

10.45 pm | 25 Jan 2023 | Business Standard

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71...
DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia

6.59 pm | 25 Jan 2023 | Business Standard

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for...
Torrent Pharma Q3 net profit up 14% to Rs 283 cr; interim dividend declared

6.26 pm | 25 Jan 2023 | Press Trust of India

Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. T...
Cipla Q3 net up 10% to Rs 801 cr, posts highest ever quarterly sales in US

5.44 pm | 25 Jan 2023 | Business Standard

Revenue up 6% to Rs 5,810 cr; firm expects US FDA audit at Goa unit
Lupin Digital launches Lyfe, a 24x7 monitoring ecosystem for heart patients

8.35 pm | 24 Jan 2023 | Business Standard

Company aims to onboard one million patients the platform, which aims to help them improve heart health through doctor-connected online and offline mo...